Cargando…
Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines
Oral vaccination has the potential to offer a safer and more efficacious approach for protection against enteric pathogens than injection-based approaches, especially in developing countries. One key advantage is the potential to induce intestinal immune responses in addition to systemic immunity. I...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230052/ https://www.ncbi.nlm.nih.gov/pubmed/34201310 http://dx.doi.org/10.3390/vaccines9060619 |
_version_ | 1783713116179136512 |
---|---|
author | Albutti, Aqel Longet, Stephanie McEntee, Craig P. Quinn, Shauna Liddicoat, Alex Rîmniceanu, Cristiana Lycke, Nils Lynch, Lydia Cardell, Susanna Lavelle, Ed C. |
author_facet | Albutti, Aqel Longet, Stephanie McEntee, Craig P. Quinn, Shauna Liddicoat, Alex Rîmniceanu, Cristiana Lycke, Nils Lynch, Lydia Cardell, Susanna Lavelle, Ed C. |
author_sort | Albutti, Aqel |
collection | PubMed |
description | Oral vaccination has the potential to offer a safer and more efficacious approach for protection against enteric pathogens than injection-based approaches, especially in developing countries. One key advantage is the potential to induce intestinal immune responses in addition to systemic immunity. In general, antigen delivery via the oral route triggers weak immune responses or immunological tolerance. The effectiveness of oral vaccination can be improved by co-administering adjuvants. However, a major challenge is the absence of potent and safe oral adjuvants for clinical application. Here, the Type II NKT cell activator sulfatide is shown for the first time to be an effective oral adjuvant for Vibrio cholerae vaccine antigens in a mouse model. Specifically, administration of sulfatide with the oral cholera vaccine Dukoral(®) resulted in enhancement of intestinal antigen-specific IgA in addition to Th1 and Th17 immune responses. In summary, sulfatide is a promising adjuvant for inclusion in an oral cholera vaccine and our data further support the potential of adjuvants targeting NKT cells in new vaccine strategies. |
format | Online Article Text |
id | pubmed-8230052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82300522021-06-26 Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines Albutti, Aqel Longet, Stephanie McEntee, Craig P. Quinn, Shauna Liddicoat, Alex Rîmniceanu, Cristiana Lycke, Nils Lynch, Lydia Cardell, Susanna Lavelle, Ed C. Vaccines (Basel) Article Oral vaccination has the potential to offer a safer and more efficacious approach for protection against enteric pathogens than injection-based approaches, especially in developing countries. One key advantage is the potential to induce intestinal immune responses in addition to systemic immunity. In general, antigen delivery via the oral route triggers weak immune responses or immunological tolerance. The effectiveness of oral vaccination can be improved by co-administering adjuvants. However, a major challenge is the absence of potent and safe oral adjuvants for clinical application. Here, the Type II NKT cell activator sulfatide is shown for the first time to be an effective oral adjuvant for Vibrio cholerae vaccine antigens in a mouse model. Specifically, administration of sulfatide with the oral cholera vaccine Dukoral(®) resulted in enhancement of intestinal antigen-specific IgA in addition to Th1 and Th17 immune responses. In summary, sulfatide is a promising adjuvant for inclusion in an oral cholera vaccine and our data further support the potential of adjuvants targeting NKT cells in new vaccine strategies. MDPI 2021-06-08 /pmc/articles/PMC8230052/ /pubmed/34201310 http://dx.doi.org/10.3390/vaccines9060619 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Albutti, Aqel Longet, Stephanie McEntee, Craig P. Quinn, Shauna Liddicoat, Alex Rîmniceanu, Cristiana Lycke, Nils Lynch, Lydia Cardell, Susanna Lavelle, Ed C. Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines |
title | Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines |
title_full | Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines |
title_fullStr | Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines |
title_full_unstemmed | Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines |
title_short | Type II NKT Cell Agonist, Sulfatide, Is an Effective Adjuvant for Oral Heat-Killed Cholera Vaccines |
title_sort | type ii nkt cell agonist, sulfatide, is an effective adjuvant for oral heat-killed cholera vaccines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230052/ https://www.ncbi.nlm.nih.gov/pubmed/34201310 http://dx.doi.org/10.3390/vaccines9060619 |
work_keys_str_mv | AT albuttiaqel typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines AT longetstephanie typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines AT mcenteecraigp typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines AT quinnshauna typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines AT liddicoatalex typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines AT rimniceanucristiana typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines AT lyckenils typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines AT lynchlydia typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines AT cardellsusanna typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines AT lavelleedc typeiinktcellagonistsulfatideisaneffectiveadjuvantfororalheatkilledcholeravaccines |